Vagus nerve stimulator
Transcutaneous vagus nerve stimulation is a real, researched category. Pulsetto's own studies, specifically, are small and haven't been peer-reviewed yet — here's the honest distinction.
Several review sites describe Pulsetto's research as a "2025 peer-reviewed study." Looking closer, the actual sources are a 2024 master's thesis and a small pilot study posted on a preprint repository — neither has gone through formal peer review.
Transcutaneous vagus nerve stimulation (tVNS) is a genuine, non-invasive neuromodulation technique — the same nerve pathway used in implanted, FDA-cleared devices for epilepsy and treatment-resistant depression.
Real, checkable regulatory certifications for the device itself — confirms it meets recognized electrical safety standards, not a claim about medical efficacy.
Stimulates both sides of the vagus nerve simultaneously — a genuine hardware differentiator from several single-side competitors.
Five built-in programs (stress, sleep, burnout, worry, pain) with session lengths of roughly 4-10 minutes, controlled through a companion app.
Studies examining Pulsetto specifically come from a 2024 master's thesis and a small 2025 preprint pilot study — not peer-reviewed journals, and often involving researchers affiliated with the company.
Real category, honestly separated from brand-specific evidence — see current pricing.
The vagus nerve is one of the most studied structures in medicine. Implanted VNS devices have decades of clinical use and FDA clearance for epilepsy and treatment-resistant depression, and a 2025 systematic review of transcutaneous VNS trials found meaningful sleep-quality improvements across studied populations.
That research evaluates the technology category broadly — not Pulsetto's specific device, frequency, or session parameters. It's real evidence that the underlying idea has merit, not proof that this particular product delivers the same results.
The research directly examining Pulsetto comes primarily from small studies with researcher affiliations to the company. A 2024 master's thesis (Erasmus University Rotterdam) reported decreased heart rate and increased HRV versus a sham group. A 2025 pilot study on the preprint repository Zenodo looked at seven patients with a chronic inflammatory condition, using self-report questionnaires.
A properly designed, sham-controlled, randomized clinical trial of Pulsetto Fit is now registered and underway — a positive sign the brand is investing in better evidence — but it hasn't been published yet. The brand's own "86% feel calmer" statistic comes from a self-selected user survey, not a controlled clinical trial.
No pressure, no fine print you have to hunt for. The answers below are the ones that actually matter before you order.
As far as we could confirm, no. The device-specific research comes from a 2024 master's thesis at Erasmus University Rotterdam and a small 2025 pilot study posted on Zenodo, a preprint repository — neither has gone through formal peer review, and both involved small sample sizes. A properly designed, sham-controlled clinical trial of Pulsetto Fit is now registered and underway, but not yet published.
Yes. Implanted VNS devices have decades of clinical use and FDA clearance for epilepsy and treatment-resistant depression, and there's substantial peer-reviewed research on transcutaneous VNS generally, including a 2025 systematic review linking it to sleep quality improvements. That research evaluates the technology category broadly, not Pulsetto's specific device or parameters.
It ships a real, FCC and CE certified physical device with a 30-day money-back guarantee and 2-year warranty. The brand's marketing statistics, including "86% of users feel calmer," come from self-selected user surveys, not controlled clinical trials — worth knowing the difference before you rely on that number.
Per the brand's own comparison, Pulsetto is priced lower than several competitors like Nurosym (around $750) and is comparable to or cheaper than Apollo Neuro and Sensate (around $349 each) — though those two use vibration rather than electrical stimulation, so the comparison isn't perfectly apples-to-apples.
Before you order: The "$546 retail" reference price used to frame the current price as a discount isn't independently verifiable — treat it the way you would any brand-stated "was" price. Pulsetto is marketed as a general wellness product and is not intended to diagnose, treat, cure, or prevent any disease or medical condition, per the brand's own disclaimer.
Transcutaneous vagus nerve stimulation, FCC and CE certified, 5 app-guided programs.